CD3-CSPG4 bispecific T cell engager: A novel platform for malignant melanoma therapy
PLOS One · 2026
DOI: 10.1371/journal.pone.0357790 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Xue Lei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The People's Hospital of Qiannan, Duyun, Guizhou, China. Hauptthemen laut MEDLINE: Melanoma, CD3 Complex, Antibodies, Bispecific, T-Lymphocytes. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Talent Support Project of Qiannan Medical College for Nationalities, Guizhou Provincial Health Commission.
Abstract (Originalsprache)
Malignant melanoma (MM) is a highly aggressive malignancy that readily metastasizes to lymph nodes and distant sites through hematogenous spread, leading to poor clinical outcomes. Therefore, there is an urgent need to develop novel therapeutic strategies. Chondroitin sulfate proteoglycan 4 (CSPG4) is one of the most frequently overexpressed proteins on malignant melanoma cells, whereas it is only expressed at very low levels in normal tissues. In this study, a novel bispecific T‑cell engager, CD3‑CSPG4/BiTE, was constructed by linking single‑chain antibodies directed against CSPG4 and CD3. In vitro assays assessed its simultaneous and specific binding to CSPG4 ⁺ melanoma cells and T cells, its capacity to drive T-cell proliferation and activation, and its ability to redirect T-cell cytotoxicity toward CSPG4 ⁺ targets. Additionally, in NOD/SCID mice bearing established human melanoma xenografts, the antitumor efficacy and systemic toxicity of the molecule were evaluated. CD3-CSPG4/BiTE was successfully generated and was shown to simultaneously bind CSPG4 ⁺ melanoma cells and T cells. Flow-cytometric analysis revealed that, compared with control constructs, CD3-CSPG4/BiTE markedly enhanced T-cell proliferation and activation (as evidenced by up-regulated CD25 and CD69) and effectively redirected T-cell–mediated lysis of CSPG4 ⁺ targets in vitro. In NOD/SCID mice bearing human melanoma xenografts, the BiTE significantly suppressed tumor growth without eliciting detectable toxicity in major organs. In summary, this study successfully developed a novel bispecific T-cell engager, CD3-CSPG4/BiTE, and demonstrated its potent antitumor activity against malignant melanoma both in vitro and in vivo. These findings provide a preclinical foundation for the clinical translation and further optimization of BiTE-based immunotherapy for melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The People's Hospital of Qiannan, Duyun, Guizhou, China.
- Department of Dermatology, The People's Hospital of Qiannan, Duyun, Guizhou, China.
ORCID-Profile: Qiang Jiang
Förderung
- Research Talent Support Project of Qiannan Medical College for Nationalities
- Guizhou Provincial Health Commission
Zitieren
APA
Lei, X., Liu, W., Luo, Z., Wu, B., Meng, Y., & Jiang, Q. (2026). CD3-CSPG4 bispecific T cell engager: A novel platform for malignant melanoma therapy. PLOS One. https://doi.org/10.1371/journal.pone.0357790
Vancouver
Lei X, Liu W, Luo Z, Wu B, Meng Y, Jiang Q. CD3-CSPG4 bispecific T cell engager: A novel platform for malignant melanoma therapy. PLOS One. 2026. doi:10.1371/journal.pone.0357790
BibTeX
@article{Lei2026,
author = {Lei, Xue and Liu, Weilan and Luo, Zongnian and Wu, Bangyong and Meng, Yu and Jiang, Qiang},
title = {CD3-CSPG4 bispecific T cell engager: A novel platform for malignant melanoma therapy},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0357790}
}
EUVIMED